FlandersBio on Twitter

Follow us on Twitter

Archive for March 2015 - News

Archive for March 2015 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

MSmetrix receives CE marking


icometrix is proud to announce its software MSmetrix has received the coveted CE mark. The MSmetrix software allows clinicians and radiologists to measure brain lesions and cerebral volumes of patients with Multiple Sclerosis (MS). Such measures have been used and validated in research protocols and clinical trials, but were not yet available for routine practice for MS. Thanks to the CE approval of MSmetrix, this advanced analysis technique is now available for individual patients in routine clinical practice. read more

Multiplicom expands its NGS product range with a MASTR kit that identifies actionable mutations in solid tumours


Multiplicom N.V. announces the release of the SOMATIC 2 MASTR™ Plus kit for the detection of actionable somatic mutations in the genes EGFR, ERBB2, PIK3CA, PIK3R1 and PTEN enabling affordable, personalised cancer treatment. read more

Galapagos: Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015


Galapagos NV (Euronext: GLPG) has the honor to invite the Shareholders, Warrant Holders, Directors and Statutory Auditor of the Company to the Annual Shareholders' Meeting that will be held on Tuesday 28 April 2015 at 2:00 p.m. (CET) at the registered office of the Company. read more

Cardio3 BioSciences sucessfully completes futility analysis of lead cardiac cell therapy C-Cure


Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in engineered cell therapy treatments, today announced the successful completion of a futility analysis for C-Cure®, its lead cell therapy for congestive heart failure, currently being evaluated in a Phase III clinical trial in Europe and Israel (CHART-1). read more

Bio-marker set forms the basis for new blood test to detect colorectal cancer


Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU Leuven - together with various European oncology centers, including UZ Leuven - have identified bio-markers that can be incorporated in a new diagnostic test. This should make it possible to detect colorectal cancer in an early stage using a simple blood test. read more

Colli-PeeTM by Novosanis wins IWT Innovation Award


Colli-PeeTM, a first void urine collection device, developed by Novosanis has received the IWT Innovation Award in the category “major social relevance”. Novosanis is very honored with this prize which was granted yesterday by The Agency for Innovation by Science and Technology. read more

Galapagos raises EUR 5.8 million through warrant exercises, Board and Executive Committee members invest


Galapagos NV (Euronext: GLPG) announced today a share capital increase arising from warrant exercises. Board members invest €2.1 million in Galapagos by exercising warrants. read more

Cardio3 BioSciences reports 2014 financial and operational results


Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of engineered cell-therapy treatments, today provided an update on recent business developments and strategic initiatives, and reported consolidated financial results for the twelve-month period ended 31 December 2014, prepared in accordance with IFRS. read more



Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced an extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, to develop and commercialise Nanobody® candidates directed towards an undisclosed voltage gated ion channel. read more

Colli-PeeTM by Novosanis nominated for IWT Innovation Award


The Agency for Innovation by Science and Technology (IWT) has nominated Colli-PeeTM, a first void urine collection device, developed by Novosanis in the category “major social relevance”. On Thursday 26th of March the winner will be announced. Novosanis is honored with this nomination. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top